Investigators Set Sights on Novel Agents Following Negative Studies in Relapsed Small Cell Lung Cancer
New agents in development including ABBV-011 and BL-B01D1 seek to turn the tides of relapsed extensive-stage small cell lung cancer; although chemoimmunotherapy has earned its right as the frontline standard of care, both classes of agents have yet to demonstrate benefit in second or later lines.
Source: onclive.com